Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26424193 | 0.88 | FOLH1 (0.72) | FOLH1CPA3 | |
| SCHEMBL23710509 | 0.85 | FOLH1 (0.44) | FOLH1 | |
| SCHEMBL26424200 | 0.85 | FOLH1 (0.44) | FOLH1 | |
| SCHEMBL23704723 | 0.85 | FOLH1 (0.62) | FOLH1CPA3 | |
| SCHEMBL7619756 | 0.81 | FOLH1 (0.72) | FOLH1CPA3 | |
| SCHEMBL26199664 | 0.78 | CETP (0.42) | FOLH1 | |
| SCHEMBL8052865 | 0.78 | FOLH1 (1.00) | FOLH1CPA3 | |
| SCHEMBL6381682 | 0.76 | FOLH1 (0.78) | FOLH1CPA3 | |
| SCHEMBL23705074 | 0.76 | FOLH1 (0.52) | FOLH1CPA3 | |
| SCHEMBL26424198 | 0.76 | FOLH1 (0.55) | FOLH1CPA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-27 | — | — | US | disclosed |
| EP-4097119-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | The Johns Hopkins University (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155167-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | SLC10A2, GPBAR1, NR1H4 | FOLH1 828/4885CPA3 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.